HK1033278A1 - Pharmaceutical preparation for use in anti-asthma therapy. - Google Patents

Pharmaceutical preparation for use in anti-asthma therapy.

Info

Publication number
HK1033278A1
HK1033278A1 HK01104076A HK01104076A HK1033278A1 HK 1033278 A1 HK1033278 A1 HK 1033278A1 HK 01104076 A HK01104076 A HK 01104076A HK 01104076 A HK01104076 A HK 01104076A HK 1033278 A1 HK1033278 A1 HK 1033278A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical preparation
asthma therapy
asthma
therapy
pharmaceutical
Prior art date
Application number
HK01104076A
Other languages
English (en)
Inventor
Nipun Davar
Atul D Ayer
Paul M Hwang
Brenda J Pollock
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of HK1033278A1 publication Critical patent/HK1033278A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
HK01104076A 1998-03-06 2001-06-13 Pharmaceutical preparation for use in anti-asthma therapy. HK1033278A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7709198P 1998-03-06 1998-03-06
PCT/US1999/004350 WO1999044592A1 (en) 1998-03-06 1999-02-26 Anti-asthma therapy

Publications (1)

Publication Number Publication Date
HK1033278A1 true HK1033278A1 (en) 2001-08-24

Family

ID=22136018

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01104076A HK1033278A1 (en) 1998-03-06 2001-06-13 Pharmaceutical preparation for use in anti-asthma therapy.

Country Status (10)

Country Link
US (1) US6224907B1 (xx)
EP (1) EP1059917B1 (xx)
JP (1) JP2002505275A (xx)
AR (1) AR018582A1 (xx)
AT (1) ATE292960T1 (xx)
AU (1) AU2882299A (xx)
DE (1) DE69924710T2 (xx)
ES (1) ES2237088T3 (xx)
HK (1) HK1033278A1 (xx)
WO (1) WO1999044592A1 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1216058A2 (en) * 1999-09-20 2002-06-26 Alza Corporation Process for lessening polymorphic conversion of a drug
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US7226422B2 (en) 2002-10-09 2007-06-05 Cardiac Pacemakers, Inc. Detection of congestion from monitoring patient response to a recumbent position
US7148248B2 (en) * 2002-11-29 2006-12-12 Masako Nozaki Method of treating or inhibiting the development of brain inflammation and sepsis
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
EP1678139B1 (en) * 2003-10-10 2011-08-31 Synhton B.V. Solid-state montelukast
BRPI0506610A (pt) * 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
US7387610B2 (en) 2004-08-19 2008-06-17 Cardiac Pacemakers, Inc. Thoracic impedance detection with blood resistivity compensation
WO2006066780A1 (en) * 2004-12-22 2006-06-29 F. Hoffmann-La Roche Ag Combinations of valategrast and montelukast for treating asthma
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US7603170B2 (en) * 2005-04-26 2009-10-13 Cardiac Pacemakers, Inc. Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance
US7907997B2 (en) 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
US9089275B2 (en) * 2005-05-11 2015-07-28 Cardiac Pacemakers, Inc. Sensitivity and specificity of pulmonary edema detection when using transthoracic impedance
JP4870402B2 (ja) * 2005-09-01 2012-02-08 小林化工株式会社 プランルカスト水和物含有錠の製造方法
US20070110802A1 (en) * 2005-11-15 2007-05-17 Janan Jona Wet granulation process
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
CN101543480A (zh) * 2008-03-28 2009-09-30 兴和株式会社 片剂
SG10201606408SA (en) 2010-08-30 2016-09-29 Sinusys Corp Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
WO2013130468A1 (en) 2012-02-29 2013-09-06 SinuSys Corporation Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
US9687263B2 (en) 2013-05-30 2017-06-27 SinuSys Corporation Devices and methods for inserting a sinus dilator
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
WO1993017709A1 (en) 1992-03-12 1993-09-16 Ono Pharmaceutical Co., Ltd. Antipruritic
DK0621032T3 (da) * 1993-04-23 2000-10-23 Novartis Ag Lægemiddelform med reguleret afgivelse
CA2161777A1 (en) * 1993-05-10 1994-11-24 Nancy M. Gray Methods and compositions using optically pure (+)-zileuton
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
CA2228610C (en) 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products

Also Published As

Publication number Publication date
EP1059917A1 (en) 2000-12-20
AR018582A1 (es) 2001-11-28
ES2237088T3 (es) 2005-07-16
ATE292960T1 (de) 2005-04-15
DE69924710D1 (de) 2005-05-19
DE69924710T2 (de) 2005-09-15
WO1999044592A1 (en) 1999-09-10
JP2002505275A (ja) 2002-02-19
AU2882299A (en) 1999-09-20
EP1059917B1 (en) 2005-04-13
US6224907B1 (en) 2001-05-01

Similar Documents

Publication Publication Date Title
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
GB9912411D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
GB9912410D0 (en) Compounds useful in therapy
GB9912416D0 (en) Compounds useful in therapy
HUP0201629A3 (en) Pharmaceutical complex containing eletriptan and cyclodextrin-derivative, pharmaceutical composition containing it, process for its preparation and its use
GB9810920D0 (en) Therapeutic use
GB9812662D0 (en) Therapeutic use
PL332783A1 (en) Pharmaceutic preparation in the form of gel
ZA994697B (en) Pharmaceutical formulation.
GB9906130D0 (en) Compounds for use in therapy
ZA99918B (en) Pharmaceutical formulation.
GB9811624D0 (en) Therapeutic use
ZA99220B (en) Triazepinones, process for their preparation and their therapeutic application.
AU2001269259A1 (en) Aryl compounds, their preparation and their use in therapy
ZA986139B (en) Sulphonamide compounds, processes for their preparation, pharmaceutical compositions containing the same and their use in therapy.
GB9812664D0 (en) Therapeutic use
GB9910770D0 (en) Compounds useul in therapy
GB9910764D0 (en) Compounds useful in therapy
GB9904691D0 (en) Compounds useful in therapy
GB9921314D0 (en) Compounds useful in therapy

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120226